[
  {
    "ts": null,
    "headline": "Jim Cramer Says “I Think Meta Has a Terrific Quarter”",
    "summary": "Meta Platforms, Inc. (NASDAQ:META) is one of the stocks on Jim Cramer’s radar recently. A caller’s top five holdings were Meta, Microsoft, Walmart, Valero, and AbbVie, and they asked if their portfolio is diversified or not. In response, Cramer said: “Okay, so Valero, the margins are really good right now with oil versus gasoline. So […]",
    "url": "https://finnhub.io/api/news?id=5fa351af4dff7e41ad31016e77759b8984dc93cf7695a473ac2f5c319bad4dd7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761667358,
      "headline": "Jim Cramer Says “I Think Meta Has a Terrific Quarter”",
      "id": 137243337,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Meta Platforms, Inc. (NASDAQ:META) is one of the stocks on Jim Cramer’s radar recently. A caller’s top five holdings were Meta, Microsoft, Walmart, Valero, and AbbVie, and they asked if their portfolio is diversified or not. In response, Cramer said: “Okay, so Valero, the margins are really good right now with oil versus gasoline. So […]",
      "url": "https://finnhub.io/api/news?id=5fa351af4dff7e41ad31016e77759b8984dc93cf7695a473ac2f5c319bad4dd7"
    }
  },
  {
    "ts": null,
    "headline": "3 Cancer-Focused Stocks Showing Strong Pipeline Progress",
    "summary": "Relay, Fate and Verastem advance promising cancer therapies, strengthening their pipelines in a rapidly evolving oncology market.",
    "url": "https://finnhub.io/api/news?id=8563a14a3ef258858ea8c55d378e17f5312e20744e165be336f0e7dd071263c1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761665700,
      "headline": "3 Cancer-Focused Stocks Showing Strong Pipeline Progress",
      "id": 137243278,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Relay, Fate and Verastem advance promising cancer therapies, strengthening their pipelines in a rapidly evolving oncology market.",
      "url": "https://finnhub.io/api/news?id=8563a14a3ef258858ea8c55d378e17f5312e20744e165be336f0e7dd071263c1"
    }
  },
  {
    "ts": null,
    "headline": "The Bottom Fishing Club - Organon: Deep Value In Drugs/Medical Products",
    "summary": "Organon stock plunged after CEO's exit and audit probe. Discover if its low valuation, global portfolio, and earnings catalysts make it a buy now.",
    "url": "https://finnhub.io/api/news?id=cf489c10d6d73c61b67e2899cb8f6f0e7b09d7f579ed86a83537732afa102807",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761660375,
      "headline": "The Bottom Fishing Club - Organon: Deep Value In Drugs/Medical Products",
      "id": 137240047,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1940034961/image_1940034961.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Organon stock plunged after CEO's exit and audit probe. Discover if its low valuation, global portfolio, and earnings catalysts make it a buy now.",
      "url": "https://finnhub.io/api/news?id=cf489c10d6d73c61b67e2899cb8f6f0e7b09d7f579ed86a83537732afa102807"
    }
  },
  {
    "ts": null,
    "headline": "Earnings Preview: Pfizer (PFE) Q3 Earnings Expected to Decline",
    "summary": "Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=33b06ffa8d302a58a4bdbb948e91d1bf9c3f365247638a78be4703b93dd5fef1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761660039,
      "headline": "Earnings Preview: Pfizer (PFE) Q3 Earnings Expected to Decline",
      "id": 137243400,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=33b06ffa8d302a58a4bdbb948e91d1bf9c3f365247638a78be4703b93dd5fef1"
    }
  },
  {
    "ts": null,
    "headline": "Allergan Aesthetics and Girls Inc., in Partnership with SkinSpirit, Inspire Future Women Leaders in STEM",
    "summary": "Today, Allergan Aesthetics, an AbbVie company, announces their continued partnership with Girls Inc. for the 7th year with programming and funding designed to foster mentorship and ensure girls have the tools and encouragement to succeed in STEM careers.",
    "url": "https://finnhub.io/api/news?id=a1ebb662f306f283d59a8ce2ceaca08d94ee5bf2fd6747bf6a43590159bea880",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761656400,
      "headline": "Allergan Aesthetics and Girls Inc., in Partnership with SkinSpirit, Inspire Future Women Leaders in STEM",
      "id": 137263658,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Today, Allergan Aesthetics, an AbbVie company, announces their continued partnership with Girls Inc. for the 7th year with programming and funding designed to foster mentorship and ensure girls have the tools and encouragement to succeed in STEM careers.",
      "url": "https://finnhub.io/api/news?id=a1ebb662f306f283d59a8ce2ceaca08d94ee5bf2fd6747bf6a43590159bea880"
    }
  },
  {
    "ts": null,
    "headline": "Should You Buy AbbVie Stock Ahead of Q3 Earnings Report?",
    "summary": "ABBV's Q3 results are likely to hinge on Skyrizi and Rinvoq growth, as Humira erosion and hefty IPR&D charges are expected to pressure near-term earnings.",
    "url": "https://finnhub.io/api/news?id=dae9b598c63a7fc801b0a53532bb7a1ede36dfbd2f989d5046955a92147676b3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761655680,
      "headline": "Should You Buy AbbVie Stock Ahead of Q3 Earnings Report?",
      "id": 137239322,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "ABBV's Q3 results are likely to hinge on Skyrizi and Rinvoq growth, as Humira erosion and hefty IPR&D charges are expected to pressure near-term earnings.",
      "url": "https://finnhub.io/api/news?id=dae9b598c63a7fc801b0a53532bb7a1ede36dfbd2f989d5046955a92147676b3"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Remains A Buy Heading Into Q3 Earnings",
    "summary": "Vertex Pharmaceuticals Incorporated remains a leader in CF treatments, fueling robust cash flow and pipeline expansions. Learn more about VRTX stock here.",
    "url": "https://finnhub.io/api/news?id=f7f84069d5333141bcb00d1a145393925dd185cb0c59c7be06da5aff41ab17af",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761652773,
      "headline": "Vertex Pharmaceuticals Remains A Buy Heading Into Q3 Earnings",
      "id": 137239695,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1386962527/image_1386962527.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Vertex Pharmaceuticals Incorporated remains a leader in CF treatments, fueling robust cash flow and pipeline expansions. Learn more about VRTX stock here.",
      "url": "https://finnhub.io/api/news?id=f7f84069d5333141bcb00d1a145393925dd185cb0c59c7be06da5aff41ab17af"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie: Deep Discount Before Earnings",
    "summary": "AbbVie Inc. is reiterated as a Strong Buy ahead of Q3 earnings, with revenue growth expected to outpace the sector median. Learn more about ABBV stock here.",
    "url": "https://finnhub.io/api/news?id=959ef2264f6e7de7d37a36642d4cdbd6e5aed9d3cf9466cf86332a9b0472c13c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761650920,
      "headline": "AbbVie: Deep Discount Before Earnings",
      "id": 137239601,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2175801616/image_2175801616.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "AbbVie Inc. is reiterated as a Strong Buy ahead of Q3 earnings, with revenue growth expected to outpace the sector median. Learn more about ABBV stock here.",
      "url": "https://finnhub.io/api/news?id=959ef2264f6e7de7d37a36642d4cdbd6e5aed9d3cf9466cf86332a9b0472c13c"
    }
  },
  {
    "ts": null,
    "headline": "Billionaire Israel \"Izzy\" Englander Has Loaded Up on This Dividend King. Should You?",
    "summary": "Englander seems to have had several good reasons to aggressively buy shares of this big drugmaker.",
    "url": "https://finnhub.io/api/news?id=e0d79e556428a11c6e13434ba04dda9b795ce5477137fd53098d312db5e4c57d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761647160,
      "headline": "Billionaire Israel \"Izzy\" Englander Has Loaded Up on This Dividend King. Should You?",
      "id": 137237790,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Englander seems to have had several good reasons to aggressively buy shares of this big drugmaker.",
      "url": "https://finnhub.io/api/news?id=e0d79e556428a11c6e13434ba04dda9b795ce5477137fd53098d312db5e4c57d"
    }
  },
  {
    "ts": null,
    "headline": "1 Unpopular Stock That Deserves a Second Chance and 2 Facing Challenges",
    "summary": "When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.",
    "url": "https://finnhub.io/api/news?id=0532c1f0932c4eb4c79222566a267b73c491ef94a1b00d1d1fdeef97eeca64e1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761625915,
      "headline": "1 Unpopular Stock That Deserves a Second Chance and 2 Facing Challenges",
      "id": 137235416,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.",
      "url": "https://finnhub.io/api/news?id=0532c1f0932c4eb4c79222566a267b73c491ef94a1b00d1d1fdeef97eeca64e1"
    }
  }
]